Filters: author is Della Pasqua [Clear All Filters]
- 2009
Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo-oxygenase inhibitors,
Eur J Pain, vol. 13, no. 5, pp. 448-57. DOI
- 2008
Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model,
J Psychiatr Res, vol. 42, no. 14, pp. 1189-97. DOI
Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy,
J Psychiatr Res, vol. 42, no. 12, pp. 1000-9. DOI
Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats,
Br J Pharmacol, vol. 153, no. 5, pp. 1072-84. DOI
Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain,
Br J Pharmacol, vol. 155, no. 7, pp. 1127-38. DOI
Prediction of attack frequency in migraine treatment,
Cephalalgia, vol. 28, no. 8, pp. 847-55. DOI
Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research,
Trends Pharmacol Sci, vol. 29, no. 4, pp. 186-91. DOI
Relevance of absorption rate and lag time to the onset of action in migraine,
Clin Pharmacokinet, vol. 47, no. 2, pp. 139-46. DOI
- 2007
Analysis of responses in migraine modelling using hidden Markov models,
Stat Med, vol. 26, no. 22, pp. 4163-78. DOI
Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis,
Annu Rev Pharmacol Toxicol, vol. 47, pp. 357-400. DOI
- 2006
A model-based approach to treatment comparison in acute migraine,
Br J Clin Pharmacol, vol. 62, no. 5, pp. 591-600. DOI
Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers,
Br J Pharmacol, vol. 148, no. 4, pp. 396-404. DOI
Prediction of headache response in migraine treatment,
Cephalalgia, vol. 26, no. 4, pp. 416-22. DOI
Markers of disease severity in chronic obstructive pulmonary disease,
Pulm Pharmacol Ther, vol. 19, no. 3, pp. 189-99. DOI
Markers of exacerbation severity in chronic obstructive pulmonary disease,
Respir Res, vol. 7, pp. 74. DOI
- 2005
Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors,
Rheumatology (Oxford), vol. 44, no. 7, pp. 846-59. DOI
- 2004
Compartmental modeling of transdermal iontophoretic transport: I. In vitro model derivation and application,
Pharm Res, vol. 21, no. 11, pp. 1974-84.
- 2001
Population pharmacokinetic-pharmacodynamic modelling of S 15535, a 5-HT(1A) receptor agonist, using a behavioural model in rats,
Eur J Pharmacol, vol. 414, no. 2-3, pp. 233-43. DOI
Pharmacokinetic-pharmacodynamic modelling in the early development phase of anti-psychotics: a comparison of the effects of clozapine, S 16924 and S 18327 in the EEG model in rats,
Br J Pharmacol, vol. 132, no. 1, pp. 151-8. DOI


